Catalyst Biosciences provides H1 2023 financials of target Beijing Continent; revenue up 21% YoY

GYRE THERAPEUTICS, INC.

BC revenue RMB379.3M, net profit RMB81.2M for H1 2023 vs revenue RMB312.7M, net profit RMB63.9M in H1 2022.
BC main product ETUARY for idiopathic pulmonary fibrosis; gross margin 96% in H1 2023.
BC total assets RMB806.6M, equity RMB707.8M as of June 30, 2023.
Catalyst's acquisition of indirect controlling interest in BC subject to stockholder approval; proxy mailed July 20, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.